ChampionX Co. (NASDAQ:CHX - Free Report) - Investment analysts at Capital One Financial lowered their FY2024 earnings per share estimates for shares of ChampionX in a research report issued to clients and investors on Monday, October 21st. Capital One Financial analyst D. Becker now forecasts that the company will post earnings per share of $1.67 for the year, down from their prior forecast of $1.97. The consensus estimate for ChampionX's current full-year earnings is $1.99 per share. Capital One Financial also issued estimates for ChampionX's Q4 2024 earnings at $0.39 EPS, Q1 2025 earnings at $0.35 EPS, Q2 2025 earnings at $0.41 EPS, Q3 2025 earnings at $0.44 EPS, Q4 2025 earnings at $0.47 EPS and FY2025 earnings at $1.67 EPS.
Separately, Piper Sandler lowered their target price on shares of ChampionX from $40.00 to $33.00 and set a "neutral" rating on the stock in a report on Monday, July 15th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $39.00.
Get Our Latest Report on ChampionX
ChampionX Stock Performance
NASDAQ:CHX traded down $0.62 during midday trading on Thursday, reaching $29.03. The stock had a trading volume of 923,530 shares, compared to its average volume of 1,868,478. The company has a quick ratio of 1.25, a current ratio of 1.99 and a debt-to-equity ratio of 0.34. The stock has a market cap of $5.53 billion, a P/E ratio of 16.11, a P/E/G ratio of 1.27 and a beta of 2.37. The firm has a fifty day simple moving average of $30.63 and a two-hundred day simple moving average of $32.43. ChampionX has a 12-month low of $25.46 and a 12-month high of $39.95.
ChampionX (NASDAQ:CHX - Get Free Report) last posted its quarterly earnings data on Wednesday, October 23rd. The company reported $0.44 earnings per share for the quarter, missing analysts' consensus estimates of $0.45 by ($0.01). The company had revenue of $906.53 million for the quarter, compared to analyst estimates of $916.50 million. ChampionX had a return on equity of 19.72% and a net margin of 8.66%. The firm's revenue was down 3.5% compared to the same quarter last year. During the same period in the previous year, the business posted $0.41 earnings per share.
Institutional Investors Weigh In On ChampionX
Several institutional investors and hedge funds have recently made changes to their positions in CHX. Allspring Global Investments Holdings LLC acquired a new stake in ChampionX in the 1st quarter worth about $27,000. Blue Trust Inc. boosted its position in shares of ChampionX by 442.4% in the third quarter. Blue Trust Inc. now owns 1,329 shares of the company's stock worth $44,000 after acquiring an additional 1,084 shares during the last quarter. DekaBank Deutsche Girozentrale acquired a new position in ChampionX during the second quarter worth approximately $68,000. UMB Bank n.a. raised its stake in ChampionX by 63.7% during the third quarter. UMB Bank n.a. now owns 2,266 shares of the company's stock worth $68,000 after purchasing an additional 882 shares during the period. Finally, Central Pacific Bank Trust Division acquired a new position in shares of ChampionX in the 1st quarter valued at $136,000. 98.99% of the stock is currently owned by hedge funds and other institutional investors.
ChampionX Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, October 4th will be paid a $0.095 dividend. This represents a $0.38 annualized dividend and a yield of 1.31%. The ex-dividend date is Friday, October 4th. ChampionX's payout ratio is currently 20.65%.
ChampionX Company Profile
(
Get Free Report)
ChampionX Corporation provides chemistry solutions, artificial lift systems, and engineered equipment and technologies to oil and gas companies worldwide. The company operates through four segments: Production Chemical Technologies, Production & Automation Technologies, Drilling Technologies, and Reservoir Chemical Technologies.
See Also
Before you consider ChampionX, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ChampionX wasn't on the list.
While ChampionX currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
